Spring Bank Pharmaceuticals Inc
Spring Bank Pharmaceuticals — Merger or Acquisition (August 2020)
38 slides from Spring Bank Pharmaceuticals's merger presentation, Aug 12, 2020
Slide 1: Redirecting T Cells. Overcoming Cancer.
August 2020 Redirecting T Cells . Overcoming Cancer . Exhibit 99.1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements Certain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities
Slide 3: Combination with Spring Bank Pharmaceuticals
Share Exchange Agreement announced on 29th July 2020 Expected to be completed in Fall of 2020 New company: F-star Therapeutics, Inc. expected to trade on NASDAQ under FSTX Dr. Eliot Forster to serve as President and CEO Combined company Board of Directors proportional to ownership spilt Financing ro
Slide 4: Highlights
Highlights F-star’s proprietary highly differentiated bispecific tetravalent platform: antibody-like manufacturing and promising safety & immunogenicity profile Exciting portfolio with four differentiated, clinical-stage assets: multiple clinical data readouts within cash runway timeframe Multiple F
Slide 5: Experienced Management Team
Experienced Management Team Medical Oncologist with 25+ years' experience in clinical research in Europe and US Experience in registrational studies, registration strategy and drug approval Louis Kayitalire CMO, MD 25+ years leading financial operations in public and private companies Proven track r
Slide 6: Our Differentiated mAb2 Bispecific Technology Suggests Clinical Benefit
Differentiated MoA (3Cs): Crosslinking, Clustering and Conditionality Established manufacturing processes and promising safety profile 2 natural binding sites 2 new binding sites (no change in structure) Fc silencing Natural human antibody format Targeted bispecific with four binding sites for stron
Slide 7: Platform Technology Offering Multiple Potential Therapeutic Opportunities
Fcab Target Status FS01 EGFR ‘plug and play ready’ FS02 HER2 ‘plug and play ready’ FS17 PD-L1 ‘plug and play ready’ FS18 LAG-3 ‘plug and play ready’ FS20 OX40 ‘plug and play ready’ FS21 Confidential Target lead optimisation FS22 CD137 ‘plug and play ready’ FS33 Confidential Target lead optimisation
Slide 8: Platform Technology Continues to be Supported by 3rd Parties
CONFIDENTIAL Platform Technology Continues to be Supported by 3rd Parties
Slide 9: 3Cs for Focused, Potent and Safe Immune Activation
Tumor cells Immune cell Clustering Crosslinking Conditionality Redirecting immune cells to a tumor Tumor cells Healthy cells 3Cs for Focused, Potent and Safe Immune Activation Reactivating exhausted immune cells Cancer directed activation Cancer Cell Killing Inducing New Biology Higher Therapeutic I
Slide 10: Bispecific Differentiation
Bispecific Differentiation Traditional Antibody Antibody Combination Heterodimeric Bispecific Antibody Alternative Scaffold Bispecific Fragment Bispecific incl BITEs F-star mAb2 Bispecific crosslinking Conditional activity Tetravalent clustering IgG-like structure
Slide 11: FS118 Has Novel Mechanism of Action
FS118 Has Novel Mechanism of Action TIL = Tumor-Infiltrating Lymphocytes Novel mechanism driven by tetravalent bispecific binding leading to crosslinking and clustering Human CD4+ T cell + DC assay
Slide 12: FS222 Potent Activity and Potential Superiority to Other Bispecific Formats
FS222 Potent Activity and Potential Superiority to Other Bispecific Formats Observed 1mg/kg (approx. 12 mice/group) Activity also observed in CT26 model Survival of MC38 tumor-bearing mice CD8+ T cell activation assay FS222 Alternative Scaffolds Heterodimer Bispecific IgG Tetravalent IgG1 Tetravalen
Slide 13: Pipeline of Next Generation Immunotherapeutics to Address Unmet Need
Pipeline of Next Generation Immunotherapeutics to Address Unmet Need 2020 mAb2 candidates 2021 Clinical Programs Targets Current Status Anticipated Next Steps Pre-clin IND Ph1 Ph2 FS118 LAG-3/PD-L1 Completion of Phase 1 trial expected in Q4:2020 Initiation of POC in acquired resistance head & neck c
Slide 14: LAG-3/PD-L1 mAb2 Bispecific Antibody
LAG-3/PD-L1 mAb² Bispecific Antibody First-in-class Novel MoA for acquired resistance patients Phase 1 initial data indicates well tolerated with long term dosing FS118 PD-L1 LAG-3 Kraman et al, Clinical Cancer Research, (2020) DOI:10.1158/1078-0432.CCR-19-3548 Note: A mAb2 is a full-length antibody
Slide 15: Checkpoint Resistant Patients Who Received Prior PD-(L)1 Therapy
CONFIDENTIAL Checkpoint Resistant Patients Who Received Prior PD-(L)1 Therapy for ≥12 weeks PD-L1 LAG-3 3+3 Ascending dose cohorts Q1W Dose Escalation and Expansion in Patients with Advanced Malignancies That Have Progressed on or After Prior PD-1/PD-L1 Containing Therapy (n = 43) Accelerated titrat
Slide 16: LAG-3 as a Clinical Biomarker of Activity
LAG-3 as a Clinical Biomarker of Activity PD-L1 LAG-3 Tumor LAG-3 (pre and post dose) Blood soluble LAG-3 (cycle 2) F-star data; sLAG-3: soluble LAG-3 Ex-vivo human T cells Clinical
Slide 17: PD-(L)1 Acquired Resistance – An Underserved Post-Checkpoint Medical Need
PD-(L)1 Acquired Resistance – An Underserved Post-Checkpoint Medical Need PD-L1 LAG-3 Stable disease (³6 month) accepted as response for acquired resistance patients Multiple lines of SOC (median 6 lines) PD-(L)1 therapy
Slide 18: FS118: Observed Disease Control of >60% in Checkpoint Acquired Resistance Patients
FS118: Observed Disease Control of >60% in Checkpoint Acquired Resistance Patients Phase 1 in Checkpoint Acquired Resistance Population Median lines pre-treatment 6 Evaluable AR patients 26 ORR (unconfirmed) 4% (1/26) DCR 62% (16/26) PD-L1 LAG-3 Primary Acquired Patients receiving 1mg/kg and above (
Slide 19: Co-expression of PD-L1 and LAG-3 is Associated with Longer Disease Control
Co-expression of PD-L1 and LAG-3 is Associated with Longer Disease Control F-star data; 15 Suitable biopsies available for analysis. PD-L1 LAG-3 Co-expression of PD-L1 and LAG-3 in acquired resistance patient tumor biopsies is associated with better outcome + - - + + + PD-L1+ tumor LAG-3+ TILs
Slide 20: Focused Proof of Concept in PD-1 Acquired Resistance Head & Neck Cancer
Focused Proof of Concept in PD-1 Acquired Resistance Head & Neck Cancer Stage 1: Futility Analysis 10 efficacy evaluable patients with co-expression of PD-L1/LAG-3 Futility analysis in 2021 Stage 2 Additional 12 efficacy evaluable patients with co-expression of PD-L1/LAG-3 Final Read out: Q4: 2022 P
Slide 21: FS120 CD137/OX40 mAb2 Bispecific Antibody
FS120 CD137/OX40 mAb² Bispecific Antibody First-in-class Dual Agonist Opportunity to Transform Current Treatment Paradigms CD137 OX40 Gaspar et al, Cancer Immunology Research, (2020) DOI: 10.1158/2326-6066.CIR-19-0798
Slide 22: CD137 (4-1BB) Comes of Age
CD137 (4-1BB) Comes of Age Multiple companies now demonstrating initial clinical activity with CD137 agonist bispecifics using tumor-associated antigens: Pieris (Her-2/CD137)1 and Roche (FAPα/CD137)2 – safe and early activity in Phase I One other CD137/OX40 molecule reported from Aptevo3 – discovery
Slide 23: Potential Stimulation of Immune Cells: Triple Immune Cell Response
+ T cell helper activity CD4+ T cell CD137 OX40 Cytotoxic T cell activity FS120 mAb² CD8+ T cell OX40 CD137 Potential Stimulation of Immune Cells: Triple Immune Cell Response CD137 OX40 Allows targeting to a wide range of tumors independent of TAA expression and FcgR binding CD4+ T cell Activates bo
Slide 24: CD137/OX40 mAb2 increases anti-tumor response to PD-1 blockade
CD137/OX40 mAb2 observed to increase the anti-tumor response to PD-1 blockade CD137/OX40 mAb2 Potently Augments the Preclinical Activity of PD-1 CD137 OX40 CT26 tumor model, PD-1 refractory (approx. 15 mice/group) Combination with PD-1
Slide 25: Expression Levels of OX40 and CD137: Low in Periphery and High in Tumor
Expression Levels of OX40 and CD137: Low in Periphery and High in Tumor Dual positive T cells CD137 OX40 Human tumor #1 Human tumor #2 CT26 Mouse model Cancer patient blood CD137 OX40 Preclinical data supports activation of immune cells via FS120 in the tumor F-star data
Slide 26: Potential Clinical Utility in Tumors That Co-express CD137 and OX40
CD137 OX40 Potential Clinical Utility in Tumors That Co-express CD137 and OX40 Bioinformatic approach to indication selection using TCGA data OX40 and CD137 co-expression T cell infiltration and Gastric Bladder PD-1 approved indications z FS120 Clinical Strategy Potential for co-stimulatory effects
Slide 27: FS120 FIH Trial Design
CONFIDENTIAL FS120 FIH Trial Design 3+3 design including optional PK/PD expansion cohorts 1 mg 100 µg 300 µg Dose Single subject cohorts ADT (28 d DLT window) 30 mg Individual subject (dose escalation) Individual subject (PK/PD expansion) Decision point (safety – DLT clearance) Decision point (safet
Slide 28: CD137/PD-L1 mAb2 Bispecific Antibody
CD137/PD-L1 mAb² Bispecific Antibody Redirecting Activated Immune Cells to the Tumor FS222 PD-L1 CD137 Lakins et al, Clinical Cancer Research, (2020): DOI: 10.1158/1078-0432.CCR-19-2958
Slide 29: FS222: Combining the Synergy of CD137 Agonism and PD-L1 Inhibition
FS222: Combining the Synergy of CD137 Agonism and PD-L1 Inhibition CD137 and PD-L1 are attractive targets for bispecific antibodies and are being pursued by a number of companies including Inhibrx, Merus, Genmab1 CD137 agonism + PD-L1 blockade results in synergistic activity with potential to improv
Slide 30: FS222: Redirecting Activated T cells to the Tumor
PD-L1 FS222 T cell CLUSTERING Tumor CD137 PD-L1 blocked CD137 agonism FS222: Redirecting Activated T cells to the Tumor PD-L1 CD137 Non PD-L1 expressing cells CROSSLINKING CONDITIONALITY Z Z Z Z Z Z PD-L1 mediated T cell exhaustion T/NK cells activation, proliferation and redirection Tumor killing,
Slide 31: Tetravalent mAb2 Activity Observed to be Superior to Combination of mAbs
Tetravalent mAb2 Activity Observed to be Superior to Combination of mAbs Tetravalent bispecific mAb2 observed to potently synergize PD-1/PD-L1 pathway inhibition with CD137 agonism 1mg/kg (approx. 12 mice/group) Activity also observed in CT26 model CD137 PD-L1 Individual spider plots 100% Tumor-free
Slide 32: Opportunity for Enhanced Efficacy in PD-L1 Low Setting
Opportunity for Enhanced Efficacy in PD-L1 Low Setting FS222 Alternative Scaffolds Heterodimer Bispecific IgG Tetravalent IgG1 Tetravalent Non-IgG Tetravalent IgG ✔ ✔ ✔ X X ✔ FS222 tetravalent format has shown potential for clinical differentiation in PD-L1 low setting CD8+ T cell activation assay w
Slide 33: Focusing on Tumors with CD137/PD-L1 Co-expression and T cell Infiltration
PD-L1 CD137 Focusing on Tumors with CD137/PD-L1 Co-expression and T cell Infiltration TCGA: The Cancer Genome Atlas CTA expected to be filed in late 2020 for FS222
Slide 34: Anticipated Clinical Plan for FS222
CONFIDENTIAL Anticipated Clinical Plan for FS222 Dose Part A PK/PD expansions: PD-L1 low-high tumors e.g. SCCHN, NSCLC, CRC MSS, Esophageal sq., STS TLS+, TNBC, Ovarian, GBM 3+3 Design & PK/PD Expansion Cohorts Safety, PK/PD, Efficacy, Biomarkers 3mg 300 µg 1mg Accelerated Dose Titration 1mg/kg Indi
Slide 35: SB 11285: An Intravenously Administered Next Generation STING Agonist
SB 11285: An Intravenously Administered Next Generation STING Agonist Second generation intravenous STING agonist Preclinical studies indicate potential advantages over intratumoral STING agonists Phase 1/2 trial including combination with PD-L1 ongoing in US Currently patients are at the 3rd dose l
Slide 36: Anticipated Future Data Milestones
Anticipated Future Data Milestones SB 11285 Ph 1/2 update: preliminary safety from IV administered STING agonist FS222 initiation of PK/PD expansion cohorts: preliminary safety and Pharmacokinetics FS222 Update on dose escalation: exploring activity and informing biomarker strategy Q3 2020 Q4 2020 Q
Slide 37: Financial History
Financial History F-star has been funded by Series A (2008 - 2013): $56M BD activities generated circa $255M BMS (2014) AbbVie (2015) Denali (2016, 2018) Merck (2017, 2019, 2020) Current Collaborations Denali – BBB platform discovery Potential future development and commercialization milestones Merc
Slide 38: Thank you
at Estar” Thank you .
Spring Bank Pharmaceuticals — Merger or Acquisition (August 2020) on 6ix